Lindsey Rolfe Clovis Oncology, Inc. (CLVS) insider trading activity

Lindsey Rolfe is Officer of Clovis Oncology, Inc.. Currently has a direct ownership of 113,691 shares of CLVS, which is worth approximately $10,232. The most recent transaction as insider was on Nov 02, 2022, when has been sold 4,261 shares (Common Stock) at a price of $0.98 per share, resulting in proceeds of $4,175. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 114K

0% 3M change

0% 12M change

Total Value Held $10,232

Lindsey Rolfe Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 02 2022	SELL Open market or private sale	$4,175 $0.98 p/Share	4,261 Reduced 3.61%	113,691 Common Stock
Nov 01 2022	BUY Exercise of conversion of derivative security	-	8,374 Added 6.73%	116,044 Common Stock
Sep 02 2022	SELL Open market or private sale	$3,054 $1.2 p/Share	2,545 Reduced 2.27%	109,578 Common Stock
Sep 01 2022	BUY Exercise of conversion of derivative security	-	5,063 Added 4.32%	112,123 Common Stock
Aug 02 2022	SELL Open market or private sale	$6,322 $1.46 p/Share	4,330 Reduced 3.89%	107,060 Common Stock
Aug 01 2022	BUY Exercise of conversion of derivative security	-	8,374 Added 7.11%	109,451 Common Stock
Jun 02 2022	SELL Open market or private sale	$1,696 $0.64 p/Share	2,650 Reduced 2.51%	103,016 Common Stock
Jun 01 2022	BUY Exercise of conversion of derivative security	-	5,062 Added 4.57%	105,666 Common Stock
May 02 2022	SELL Open market or private sale	$8,376 $1.97 p/Share	4,252 Reduced 4.06%	100,604 Common Stock
May 01 2022	BUY Exercise of conversion of derivative security	-	8,374 Added 7.52%	102,952 Common Stock
Mar 02 2022	SELL Open market or private sale	$20,467 $1.87 p/Share	10,945 Reduced 10.19%	96,482 Common Stock
Mar 01 2022	BUY Exercise of conversion of derivative security	-	20,938 Added 16.36%	107,067 Common Stock
Feb 02 2022	SELL Open market or private sale	$8,757 $1.94 p/Share	4,514 Reduced 4.96%	86,489 Common Stock
Feb 01 2022	BUY Exercise of conversion of derivative security	-	8,375 Added 8.6%	88,982 Common Stock
Dec 02 2021	SELL Open market or private sale	$1,038 $3.0 p/Share	346 Reduced 0.42%	82,628 Common Stock
Dec 01 2021	BUY Exercise of conversion of derivative security	-	687 Added 0.82%	82,974 Common Stock
Nov 02 2021	SELL Open market or private sale	$19,151 $4.55 p/Share	4,209 Reduced 4.87%	82,287 Common Stock
Nov 01 2021	BUY Exercise of conversion of derivative security	-	8,374 Added 9.01%	84,612 Common Stock
Sep 02 2021	SELL Open market or private sale	$1,697 $4.89 p/Share	347 Reduced 0.44%	78,122 Common Stock
Sep 01 2021	BUY Exercise of conversion of derivative security	-	688 Added 0.87%	78,469 Common Stock
Aug 03 2021	SELL Open market or private sale	$20,220 $4.82 p/Share	4,195 Reduced 5.12%	77,781 Common Stock
Aug 01 2021	BUY Exercise of conversion of derivative security	-	8,374 Added 9.47%	80,098 Common Stock
Jun 03 2021	SELL Open market or private sale	$1,813 $5.63 p/Share	322 Reduced 0.44%	73,602 Common Stock
Jun 01 2021	BUY Exercise of conversion of derivative security	-	687 Added 0.92%	73,924 Common Stock
May 04 2021	SELL Open market or private sale	$24,936 $5.54 p/Share	4,501 Reduced 5.79%	73,237 Common Stock

Also insider at

BCEL

Atreca, Inc. Healthcare

Director

PBAXU

PHOENIX BIOTECH ACQUISITION CORP. Financial Services

Director

Lindsey Rolfe

Officer

Boulder, CO

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CLVS shares.

Notify only if

Value

Insider Trading

Get notified when an Clovis Oncology, Inc. insider buys or sells CLVS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Clovis Oncology, Inc.

Track Activities on CLVS

Account